
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1251690/publications.pdf Version: 2024-02-01



Ζηένιτιν Υγνς

#	Article	IF	CITATIONS
1	Optimization in Chemical Modification of Single-Stranded siRNA Encapsulated by Neutral Cytidinyl/Cationic Lipids. Frontiers in Chemistry, 2022, 10, 843181.	3.6	0
2	Activity and Tissue Distribution of Antisense Oligonucleotide CT102 Encapsulated with Cytidinyl/Cationic Lipid against Hepatocellular Carcinoma. Molecular Pharmaceutics, 2022, 19, 4552-4564.	4.6	6
3	Recent Progress in Aptamer Discoveries and Modifications for Therapeutic Applications. ACS Applied Materials & Interfaces, 2021, 13, 9500-9519.	8.0	287
4	A G-quadruplex nanoswitch in the SGK1 promoter regulates isoform expression by K+/Na+ balance and resveratrol binding. Biochimica Et Biophysica Acta - General Subjects, 2021, 1865, 129778.	2.4	6
5	Selective Anti-melanoma Effect of Phosphothioated Aptamer Encapsulated by Neutral Cytidinyl/Cationic Lipids. Frontiers in Cell and Developmental Biology, 2021, 9, 660233.	3.7	3
6	Feasibility of cRGD conjugation at 5′-antisense strand of siRNA by phosphodiester linkage extension. Molecular Therapy - Nucleic Acids, 2021, 25, 603-612.	5.1	8
7	Rational preparation and application of a mRNA delivery system with cytidinyl/cationic lipid. Journal of Controlled Release, 2021, 340, 114-124.	9.9	11
8	Overcoming the delivery barrier of oligonucleotide drugs and enhancing nucleoside drug efficiency: The use of nucleolipids. Medicinal Research Reviews, 2020, 40, 1178-1199.	10.5	12
9	Replication of DNA Containing Mirror-Image Thymidine in <i>E. coli</i> Cells. Chemical Research in Toxicology, 2020, 33, 2276-2285.	3.3	3
10	siRNA Packaged with Neutral Cytidinyl/Cationic/PEG Lipids for Enhanced Antitumor Efficiency and Safety <i>In Vitro</i> and <i>In Vivo</i> . ACS Applied Bio Materials, 2020, 3, 6297-6309.	4.6	8
11	Construction of a Targeting Nanoparticle of 3′,3″-Bis-Peptide-siRNA Conjugate/Mixed Lipid with Postinserted DSPE-PEG2000-cRGD. Molecular Pharmaceutics, 2019, 16, 4920-4928.	4.6	17
12	An oligonucleotide synthesizer based on a microreactor chip and an inkjet printer. Scientific Reports, 2019, 9, 5058.	3.3	22
13	Reversible Photocontrol of Thrombin Activity by Replacing Loops of Thrombin Binding Aptamer using Azobenzene Derivatives. Bioconjugate Chemistry, 2019, 30, 231-241.	3.6	16
14	Structural optimization and additional targets identification of antisense oligonucleotide G3139 encapsulated in a neutral cytidinyl-lipid combined with a cationic lipid in vitro and in vivo. Biomaterials, 2019, 197, 182-193.	11.4	28
15	Synthesis and Evaluation of Novel Neamine–Nucleoside Conjugates as Potential Antibiotic Targets for Escherichia coli 16S Ribosomal RNA. Methods in Molecular Biology, 2019, 1870, 151-163.	0.9	0
16	Chemical modifications of nucleic acid drugs and their delivery systems for geneâ€based therapy. Medicinal Research Reviews, 2018, 38, 829-869.	10.5	108
17	Delivery Pathway Regulation of 3′,3″-Bis-Peptide-siRNA Conjugate via Nanocarrier Architecture Engineering. Molecular Therapy - Nucleic Acids, 2018, 10, 75-90.	5.1	15
18	<scp>d</scp> -/ <scp>l</scp> -lsothymidine incorporation in the core sequence of aptamer BC15 enhanced its binding affinity to the hnRNP A1 protein. Organic and Biomolecular Chemistry, 2018, 16, 7488-7497.	2.8	5

#	Article	IF	CITATIONS
19	Caged siRNAs with single folic acid modification of antisense RNA for photomodulation of exogenous and endogenous gene expression in cells. Organic and Biomolecular Chemistry, 2018, 16, 7029-7035.	2.8	8
20	Anticancer effects of combinational treatment with BRAFV600E siRNA and PI3K pathway inhibitors in melanoma cell lines harboring BRAFV600E. Oncology Letters, 2018, 16, 632-642.	1.8	6
21	Annealing novel nucleobase-lipids with oligonucleotides or plasmid DNA based on H-bonding or ï€-ï€ interaction: Assemblies and transfections. Biomaterials, 2018, 178, 147-157.	11.4	31
22	Assembly And Transfection Of Novel Nucleobase-Lipids. , 2018, , .		0
23	Isonucleotide incorporation into middle and terminal siRNA duplexes exhibits high gene silencing efficacy and nuclease resistance. Organic and Biomolecular Chemistry, 2017, 15, 5161-5170.	2.8	6
24	Alkylation of phosphorothioated thrombin binding aptamers improves the selectivity of inhibition of tumor cell proliferation upon anticoagulation. Biochimica Et Biophysica Acta - General Subjects, 2017, 1861, 1864-1869.	2.4	14
25	Chemical modification improves the stability of the DNA aptamer GBI-10 and its affinity towards tenascin-C. Organic and Biomolecular Chemistry, 2017, 15, 1174-1182.	2.8	21
26	The Bioactivity of D-/L-Isonucleoside- and 2′-Deoxyinosine-Incorporated Aptamer AS1411s Including DNA Replication/MicroRNA Expression. Molecular Therapy - Nucleic Acids, 2017, 9, 218-229.	5.1	24
27	Site-Specific Modification Using the 2′-Methoxyethyl Group Improves the Specificity and Activity of siRNAs. Molecular Therapy - Nucleic Acids, 2017, 9, 242-250.	5.1	28
28	Mirror-Image Thymidine Discriminates against Incorporation of Deoxyribonucleotide Triphosphate into DNA and Repairs Itself by DNA Polymerases. Bioconjugate Chemistry, 2017, 28, 2125-2134.	3.6	10
29	Preparation and In Vitro Evaluation of a MRI Contrast Agent Based on Aptamer-Modified Gadolinium-Loaded Liposomes for Tumor Targeting. AAPS PharmSciTech, 2017, 18, 1564-1571.	3.3	10
30	Reductive nanocomplex encapsulation of cRGD-siRNA conjugates for enhanced targeting to cancer cells. International Journal of Nanomedicine, 2017, Volume 12, 7255-7272.	6.7	16
31	Transfection of 3′,3′′-bis-peptide-siRNA conjugate by cationic lipoplexes mixed with a neutral cytosin-1-yl-lipid. Journal of Chinese Pharmaceutical Sciences, 2017, 26, .	0.1	4
32	Bioactivity of 2′-deoxyinosine-incorporated aptamer AS1411. Scientific Reports, 2016, 6, 25799.	3.3	35
33	RGD peptide conjugation results in enhanced antitumor activity of PD0325901 against glioblastoma by both tumor-targeting delivery and combination therapy. International Journal of Pharmaceutics, 2016, 505, 329-340.	5.2	45
34	The decreased N6-methyladenine DNA modification in cancer cells. Biochemical and Biophysical Research Communications, 2016, 480, 120-125.	2.1	31
35	A subunit vaccine based on rH-NS induces protection againstMycobacterium tuberculosisinfection by inducing the Th1 immune response and activating macrophages. Acta Biochimica Et Biophysica Sinica, 2016, 48, 909-922.	2.0	3
36	Differential TGFβ pathway targeting by miR-122 in humans and mice affects liver cancer metastasis. Nature Communications, 2016, 7, 11012.	12.8	47

ZHENJUN YANG

#	Article	IF	CITATIONS
37	tRNA modification profiles of the fast-proliferating cancer cells. Biochemical and Biophysical Research Communications, 2016, 476, 340-345.	2.1	33
38	The role of disulfide-bridge on the activities of H-shape gemini-like cationic lipid based siRNA delivery. Journal of Controlled Release, 2016, 235, 99-111.	9.9	21
39	Biological Properties of a 3′,3″-Bis-Peptide-siRNA Conjugate in Vitro and in Vivo. Bioconjugate Chemistry, 2016, 27, 1131-1142.	3.6	13
40	Spatial conservation studies of nucleobases in 10–23 DNAzyme by 2′-positioned isonucleotides and enantiomers for increased activity. Organic and Biomolecular Chemistry, 2016, 14, 4032-4038.	2.8	9
41	Recent progress on siRNA conjugates. Scientia Sinica Chimica, 2016, 46, 633-642.	0.4	0
42	Diminished serum repetin levels in patients with schizophrenia and bipolar disorder. Scientific Reports, 2015, 5, 7977.	3.3	3
43	Supramolecular Assembly Models of siRNA Delivery Systems. Chinese Journal of Chemistry, 2015, 33, 79-89.	4.9	9
44	Supramolecular assemblies of novel aminonucleoside phospholipids and their bonding to nucleic acids. Chemical Communications, 2015, 51, 469-472.	4.1	13
45	Studies on the preferred uracil–adenine base pair at the cleavage site of 10–23 DNAzyme by functional group modifications on adenine. Bioorganic and Medicinal Chemistry, 2015, 23, 4256-4263.	3.0	7
46	<scp>d</scp> -lsonucleotide (isoNA) incorporation around cleavage site of passenger strand promotes the vibration of Ago2-PAZ domain and enhances in vitro potency of siRNA. Organic and Biomolecular Chemistry, 2015, 13, 10825-10833.	2.8	4
47	Exploring Directional Invasion of Serum Nuclease into siRNA Duplexes by Asymmetrical Terminal Modifications. ChemMedChem, 2014, 9, 2111-2119.	3.2	6
48	A novel method for the synthesis of sulfur substituted-cyclopyrophosphate of cADPR analogs. Chinese Chemical Letters, 2014, 25, 1583-1585.	9.0	0
49	Nucleolin-targeting liposomes guided by aptamer AS1411 for the delivery of siRNA for the treatment of malignant melanomas. Biomaterials, 2014, 35, 3840-3850.	11.4	234
50	Loss of silencing activity caused by 5′-terminal modification with d-/l-isonucleotide (isoNA) or locked nucleic acid (LNA) could not be restored by 5′-terminal phosphorylation. Science China Chemistry, 2014, 57, 329-334.	8.2	3
51	Stability and bioactivity of thrombin binding aptamers modified with <scp>d</scp> -/ <scp>l</scp> -isothymidine in the loop regions. Organic and Biomolecular Chemistry, 2014, 12, 8866-8876.	2.8	38
52	A novel gemini-like cationic lipid for the efficient delivery of siRNA. New Journal of Chemistry, 2014, 38, 4952-4962.	2.8	18
53	Unfolding and Conformational Variations of Thrombinâ€Binding DNA Aptamers: Synthesis, Circular Dichroism and Molecular Dynamics Simulations. ChemMedChem, 2014, 9, 993-1001.	3.2	15
54	Serum stability enhancement of siRNA caused by peptide conjugation at 3'-terminus of sense strand. Journal of Chinese Pharmaceutical Sciences, 2014, 23, .	0.1	1

#	Article	IF	CITATIONS
55	Long Double-Stranded Multiplex siRNAs for Dual Genes Silencing. Nucleic Acid Therapeutics, 2013, 23, 281-288.	3.6	9
56	Design, synthesis and biological evaluation of indolizine derivatives as HIV-1 VIF–ElonginC interaction inhibitors. Molecular Diversity, 2013, 17, 221-243.	3.9	41
57	Thymidine-based amphiphiles and their bonding to DNA. New Journal of Chemistry, 2013, 37, 1122.	2.8	4
58	BODIPY-based sulfoxide: Synthesis, photophysical characterization and response to benzenethiols. Dyes and Pigments, 2013, 96, 328-332.	3.7	35
59	Effects of Conformational Alteration Induced by d-/l-Isonucleoside Incorporation in siRNA on Their Stability in Serum and Silencing Activity. Bioconjugate Chemistry, 2013, 24, 951-959.	3.6	18
60	Indolizine Derivatives as <scp>HIV</scp> â€1 <scp>VIF</scp> –Elongin <scp>C</scp> Interaction Inhibitors. Chemical Biology and Drug Design, 2013, 81, 730-741.	3.2	46
61	Synthesis and Antitumor Activity Evaluation of <i>l³</i> â€Monofluorinated and <i>l³</i> , <i>l³</i> â€Difluorinated Goniothalamin Analogues. Chinese Journal of Chemistry, 2013, 31, 805-812.	4.9	8
62	Synthesis and biological evaluation of peptide-siRNA conjugates with phosphodiester unit as linker. Science China Chemistry, 2013, 56, 1542-1549.	8.2	5
63	Synthesis and Antiâ€HIV Activity of a Series of 6â€Modified 2′,3′â€Dideoxyguanosine and 2′,3′â€Didehydroâ€2′,3′â€dideoxyguanosine Analogs. Chinese Journal of Chemistry, 2013, 31, 1207-	1218.	4
64	Synthesis and Biological Evaluation of RGD-Conjugated MEK1/2 Kinase Inhibitors for Integrin-Targeted Cancer Therapy. Molecules, 2013, 18, 13957-13978.	3.8	15
65	Modification of oligonucleotides by isonucleosides incorporation and peptides conjugation. Journal of Chinese Pharmaceutical Sciences, 2012, 21, .	0.1	0
66	Manipulation of gene expression in zebrafish using caged circular morpholino oligomers. Nucleic Acids Research, 2012, 40, 11155-11162.	14.5	58
67	Synthesis and Calcium Mobilization Activity of cADPR Analogues Which Integrate Nucleobase, Northern and Southern Ribose Modifications. Molecules, 2012, 17, 4343-4356.	3.8	7
68	Synthesis, physicochemical and biological properties of oligonucleotides incorporated with amino-isonucleosides. Science China Chemistry, 2012, 55, 70-79.	8.2	6
69	Studies on the Synthesis of Nicotinamide Nucleoside and Nucleotide Analogues and Their Inhibitions towards CD38 NADase. Heterocycles, 2011, 83, 2837.	0.7	11
70	Synthesis and SAR Study of Novel Peptide Aldehydes as Inhibitors of 20S Proteasome. Molecules, 2011, 16, 7551-7564.	3.8	16
71	Synthesis of Salinosporamide A and Its Analogs as 20S Proteasome Inhibitors and SAR Summarization. Current Topics in Medicinal Chemistry, 2011, 11, 2906-2922.	2.1	3
72	Qualitative and Quantitative Determination of Oligonucleotides by Non-Gel Capillary Electrophoresis. Chromatographia, 2011, 73, 579-582.	1.3	2

#	Article	IF	CITATIONS
73	Studies on the adenosine deaminase-catalyzed conversion of adenosine and nucleoside prodrugs by different capillary electrophoresis modes. Analytical Biochemistry, 2011, 414, 131-137.	2.4	14
74	Study on steady-state kinetics of nucleotide analogues incorporation by non-gel CE. Electrophoresis, 2010, 31, 507-511.	2.4	3
75	Novel nucleobase-simplified cyclic ADP-ribose analogue: A concise synthesis and Ca2+-mobilizing activity in T-lymphocytes. Organic and Biomolecular Chemistry, 2010, 8, 1843.	2.8	16
76	Concise Syntheses of Trifluoromethylated Cyclic and Acyclic Analogues of cADPR. Molecules, 2010, 15, 8689-8701.	3.8	11
77	Concise synthesis of novel acyclic analogues of cADPR with an ether chain as the northern moiety. New Journal of Chemistry, 2010, 34, 956.	2.8	6
78	Synthesis and biological evaluation of novel neamine–nucleoside conjugates potentially targeting to RNAs. Tetrahedron, 2009, 65, 5228-5239.	1.9	21
79	In vitro selection of G-rich RNA aptamers that target HIV-1 integrase. Science in China Series B: Chemistry, 2008, 51, 401-413.	0.8	2
80	Synthesis and recognition of novel isonucleoside triphosphates by DNA polymerases. Bioorganic and Medicinal Chemistry, 2007, 15, 3019-3025.	3.0	23
81	Mechanism of Anti-Human Immunodeficiency Virus Activity of β- d -6-Cyclopropylamino-2′,3′-Didehydro-2′,3′-Dideoxyguanosine. Antimicrobial Agents and Chemotherap 2005, 49, 1994-2001.	y,3.2	5
82	Novel Use of a Guanosine Prodrug Approach To Convert 2',3'-Didehydro-2',3'-Dideoxyguanosine into a Viable Antiviral Agent. Antimicrobial Agents and Chemotherapy, 2002, 46, 887-891.	3.2	36
83	Insights into the Molecular Mechanism of Inhibition and Drug Resistance for HIV-1 RT with Carbovir Triphosphateâ€. Biochemistry, 2002, 41, 5150-5162.	2.5	42
84	Synthesis and Duplex Stabilization of Oligonucleotides Consisting of Isonucleosides. Helvetica Chimica Acta, 1999, 82, 2037-2043.	1.6	19